Loading...
Market
Which age group will be targeted in the next phase of Moderna's mRNA norovirus vaccine trial by March 2025?
2
Resolution / Starting Odds
Children under 12 • 25%
Adults 18-65 • 25%
Elderly 65+ • 25%
All age groups • 25%
Official announcement from Moderna or NHS detailing the next phase of the trial
Story
NHS Seeks Volunteers for World's First Norovirus Vaccine Trial to Prevent Thousands of Hospitalizations
Oct 23, 2024, 07:58 AM
The UK's National Health Service (NHS) is set to trial the world's first mRNA vaccine against norovirus, commonly known as the winter vomiting bug. The vaccine, developed by Moderna, aims to immunize people against the highly contagious virus, which is linked to around 12,000 hospital admissions in the UK each year. British volunteers are being sought to participate in the innovative trial, which will open across the UK, including at the Royal Victoria Infirmary (RVI), over the next two weeks. Initial results have shown that the jab creates a "strong immune response," and experts believe it could prevent thousands of hospitalizations annually and ease pressure on the NHS during winter. If successful, the vaccine could be available as soon as 2026.
View original story
Similar markets
Successful efficacy • 25%
Partial efficacy • 25%
No efficacy • 25%
Trial discontinued • 25%
Highly effective • 25%
Moderately effective • 25%
Slightly effective • 25%
Ineffective • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
2-12 years • 25%
13-29 years • 25%
30-49 years • 25%
Equal uptake across all age groups • 25%
Successful with no major side effects • 25%
Successful with some side effects • 25%
Unsuccessful • 25%
Inconclusive • 25%
UK MHRA • 25%
US FDA • 25%
European Medicines Agency • 25%
Other • 25%
Children (6 months to 11 years) • 25%
Adolescents (12 to 17 years) • 25%
Adults (18 to 64 years) • 25%
Seniors (65 years and older) • 25%
Yes • 50%
No • 50%
Less than 1,000 • 25%
1,000 to 5,000 • 25%
5,001 to 10,000 • 25%
More than 10,000 • 25%